This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Trial of efficacy of synthetic vs. animal surfactant

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

GESTATION: A RAMDOMISED TRIAL

The trial compared the efficacy of a synthetic surfactant (Pumactant) and an animal-derived surfactant (Poractant alfa) in premature neonates with respiratory distress syndrome.

The primary end-point was duration of high-dependency care. The secondary end-point was mortality.

Reference:

  • 1) Ainsworth, SB, Beresford, MW. et al. (2000). Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet, 355, 1387-92

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.